Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Will Aegerion Need Another TV Interview To Satisfy FDA After Juxtapid Citation?

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA asks for correction in warning letter objecting to CEO statements on CNBC’s “Fast Money” that touted the rare lipid disorder treatment.

You may also be interested in...



Voice of the Patient: Peer “Ambassadors” Help Recruitment at Aegerion

In the ultra-orphan, ultra-priced segment where the recruitment of each patient is a major commercial event, the voice of existing patients can be very important.

Aegerion Resolves FDA Warning About Juxtapid Promotion But DOJ Probe Continues

Corrective broadcast clarifying statements its CEO made on CNBC’s “Fast Money” produces a close-out letter, but the firm emphasizes the cost and risks of a DOJ investigation.

Voice of the Patient: Peer “Ambassadors” Help Recruitment at Aegerion

In the ultra-orphan, ultra-priced segment where the recruitment of each patient is a major commercial event, the voice of existing patients can be very important.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS075031

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel